share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Announces Commencement Of The HUMAN Phase I Clinical Trial With SAB-142, A Potential Disease-Modifying Treatment For Type 1 Diabetes

Benzinga ·  Nov 29, 2023 07:00
EXCLUSIVE: SAB Biotherapeutics Tells Benzinga Co. Announces Commencement Of The HUMAN Phase I Clinical Trial With SAB-142, A Potential Disease-Modifying Treatment For Type 1 Diabetes
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment